Funding
This work was supported by the National Natural Science Foundation of China (No. 81970711, 81670751 and 81000329).
1. Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic Stellate Cell Activation and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets? Biomedicines. 2021 Mar 31;9(4):365.
2. Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020 Apr;17(4):e1003100.
3. Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol. 2020 Sep 27;12(9):533–57.
4. Manilla V, Santopaolo F, Gasbarrini A, Ponziani FR. Type 2 Diabetes Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to Cancer. Nutrients. 2023 May 29;15(11):2521.
5. Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Gastroenterology. 2022 Sep;163(3):764-774.e1.
6. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019 Jun;42(6):1147–54.
7. Zhou P, Tan Y, Hao Z, Xu W, Zhou X, Yu J. Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1144838.
8. Zhao DM, Li CQ, Sun YM, Fan JY, Wu N, Sun YN, et al. Sodium glucose cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty liver disease by ameliorating dipeptidyl-peptidase-4 protein expression in diabetic mice. Endokrynol Pol. 2023;74(2):190–6.
9. Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, et al. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatol Commun. 2022 Jan;6(1):120–32.
10. Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, et al. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab. 2021;12:20420188211000244.
11. Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza Babaei M, et al. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther. 2020 Nov;37(11):4697–708.
12. Hata S, Okamura T, Kobayashi A, Bamba R, Miyoshi T, Nakajima H, et al. Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice. Nutrients. 2022 Aug 27;14(17):3531.
13. Lecamwasam A, Ekinci EI. Novel Associations of Empagliflozin on the Gut Microbiome and Metabolome in Type 2 Diabetes. J Clin Endocrinol Metab. 2022 Sep 28;107(10):e4246–7.
14. Hao H, Li Z, Qiao SY, Qi Y, Xu XY, Si JY, et al. Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora. Atherosclerosis. 2023 Apr;371:32–40.
15. Deng L, Yang Y, Xu G. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Dec;1867(12):159234.
16. Yao Q, Yu Z, Meng Q, Chen J, Liu Y, Song W, et al. The role of small intestinal bacterial overgrowth in obesity and its related diseases. Biochem Pharmacol. 2023 Jun;212:115546.
17. Qin J, Ling X, Wang Q, Huang Z, Guo B, Zhang C, et al. Integrated Gut Microbiota and Urine Metabolite Analyses of T2DM with NAFLD Rat Model. Appl Biochem Biotechnol. 2023 Mar 4;
18. Xu J, Lv H. PSTPIP2 alleviates obesity associated adipose tissue inflammation and insulin resistance in diabetes mice through promoting M2 macrophage polarization via activation of PPARγ. J Diabetes Complications. 2023 Jun;37(6):108479.
19. Jonker AM, Dijkhuis FW, Boes A, Hardonk MJ, Grond J. Immunohistochemical study of extracellular matrix in acute galactosamine hepatitis in rats. Hepatology. 1992 Mar;15(3):423–31.
20. Jiang Y, Zhu L, Wu D, Ni Y, Huang C, Ye H, et al. Type IIB PKA is highly expressed in β cells and controls cell proliferation via regulating Cyclin D1 expression. FEBS J. 2022 May;289(10):2865–76.
21. Li L, Li Q, Huang W, Han Y, Tan H, An M, et al. Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway. Front Pharmacol. 2021;12:589273.
22. Delgado TC, de Las Heras J, Martínez-Chantar ML. Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease. Front Endocrinol (Lausanne). 2022;13:1058101.
23. ElBaset MA, Salem RS, Ayman F, Ayman N, Shaban N, Afifi SM, et al. Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis. Antioxidants (Basel). 2022 Oct 30;11(11):2152.
24. Bischoff SC, Ockenga J, Eshraghian A, Barazzoni R, Busetto L, Campmans-Kuijpers M, et al. Practical guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline. Clin Nutr. 2023 Apr 10;42(6):987–1024.
25. Gairing SJ, Schleicher EM, Labenz C. Diabetes mellitus - risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis? Metab Brain Dis. 2023 Jun;38(5):1691–700.
26. Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 2019 Jun;45(3):213–23.
27. Meng Z, Liu X, Li T, Fang T, Cheng Y, Han L, et al. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Int Immunopharmacol. 2021 May;94:107492.
28. Wu J, Chen Y, Yang H, Gu L, Ni Z, Mou S, et al. Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice. Front Endocrinol (Lausanne). 2023;14:1026040.
29. Li Z, Dong J, Wang M, Yan J, Hu Y, Liu Y, et al. Resveratrol ameliorates liver fibrosis induced by nonpathogenic Staphylococcus in BALB/c mice through inhibiting its growth. Mol Med. 2022 May 4;28(1):52.
30. Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship. Hepatol Commun. 2019 Apr;3(4):456–70.
31. Kabiri-Arani S, Motallebi M, Taheri MA, Kheiripour N, Ardjmand A, Aghadavod E, et al. The Effect of Heat-Killed Lactobacillus plantarum on Oxidative Stress and Liver Damage in Rats with Bile Duct Ligation-Induced Hepatic Fibrosis. Probiotics Antimicrob Proteins. 2022 Dec 16;
32. Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, et al. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice. Hepatology. 2020 Jun;71(6):2050–66.
33. Chi X, Cheng DY, Sun X, Liu SA, Wang RB, Chen Q, et al. Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis: A Randomized Double-Blind Controlled Trial. Chin J Integr Med. 2023 May 24;
34. Henke MT, Kenny DJ, Cassilly CD, Vlamakis H, Xavier RJ, Clardy J. Ruminococcus gnavus, a member of the human gut microbiome associated with Crohn’s disease, produces an inflammatory polysaccharide. Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12672–7.
35. Wang X, Hao W, Huang X, Duan Z. Lower blood lipid level from the administration of plant tannins via altering the gut microbiota diversity and structure. Food Funct. 2023 May 22;14(10):4847–58.
36. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012 Feb 28;18(8):727–35.
37. Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T. Gut-liver axis: barriers and functional circuits. Nat Rev Gastroenterol Hepatol. 2023 Apr 21;
38. Turroni F, Ventura M, Buttó LF, Duranti S, O’Toole PW, Motherway MO, et al. Molecular dialogue between the human gut microbiota and the host: a Lactobacillus and Bifidobacterium perspective. Cell Mol Life Sci. 2014 Jan;71(2):183–203.
39. Su L, Zeng Y, Li G, Chen J, Chen X. Quercetin improves high-fat diet-induced obesity by modulating gut microbiota and metabolites in C57BL/6J mice. Phytother Res. 2022 Dec;36(12):4558–72.
40. Hoareau L, Buyse M, Festy F, Ravanan P, Gonthier MP, Matias I, et al. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. Obesity (Silver Spring). 2009 Mar;17(3):431–8.
41. Oyebode OA, Erukainure OL, Ibeji C, Koorbanally NA, Islam MS. Crassocephalum rubens, a leafy vegetable, suppresses oxidative pancreatic and hepatic injury and inhibits key enzymes linked to type 2 diabetes: An ex vivo and in silico study. J Food Biochem. 2019 Aug;43(8):e12930.